HOME >> BIOLOGY >> NEWS
Second generation targeted antibodies - It's all in the binding

The overproduction, or 'overexpression', of the epidermal growth factor receptor (EGFR) is one of the most common aberrations in cancer, and subsequently agents that inhibit EGFR are among the most hotly-pursued potential products in the pharmaceutical industry. Now, just weeks after one of the first anti-EGFR antibodies, ImClone's Erbitux (Cetuximab), was approved for use in Europe and the USA, a 'second generation' anti-EGFR antibody is set to enter early-phase clinical trials in Australia. In two articles recently published in the Journal of Biological Chemistry, research teams from the Melbourne Branch of the international Ludwig Institute for Cancer Research (LICR) have elucidated the unique binding properties of an anti-EGFR antibody, called 806, that is able to discriminate between EGFR molecules on cancer cells and EGFR molecules on normal cells.

"There is already one anti-EGFR antibody on the market, and there are several more in clinical trials," says Dr. Andrew Scott, the Head of the LICR Melbourne Branch's Clinical Program. "Although these anti-EGFR antibodies do show some anti-tumor activity in patients, they are far from ideal because they bind to EGFR on both cancer cells and normal cells. As a result, they target normal tissues as well as the tumor, and side-effects, although mild, are common." Perhaps more importantly, the 'first generation' antibodies are limited in their clinical application and their capacity for improvement. "We need to increase the therapeutic efficacy of the available anti-EGFR antibodies," explains Dr. Scott. "What we would like to do is attach a lethal agent to an anti-EGFR antibody, such as a cytotoxic molecule or a radioisotope, so that the agent is targeted directly to the cancer cell. With the 806 antibody, we should be able to both interfere with EGFR signaling and deliver lethal agents to cancers, without causing severe side-effects through the destruction of normal, healthy cells, particularly in the liver an
'"/>

Contact: Sarah L. White, Ph.D.
swhite@licr.org
212-450-1543
Ludwig Institute for Cancer Research
6-May-2004


Page: 1 2 3

Related biology news :

1. Second call for proposals for the European Young Investigator Award
2. Secondary complications and restoration of function in SCI
3. Second EMBO International Practical Workshop for Science Teachers
4. NTP-CERHR announces the Second Phthalates Expert Panel Meeting to be held December 15-17, 1999
5. In Logged Forests, Hunting of Wildlife Becomes Deadly Second Harvest
6. Iron Supplemented Formula Milk Should Be Free For Inner City Children Into Their Second Year Of Life
7. Oregon Scientists Discover A Second Blood-Brain Barrier; Important Finding For Patients With Brain Cancers And Neurological Disorders
8. When One Gene Has Two Roles, Its Second Function May Be Missed
9. Phase III Results Suggest Potent Antiviral Activity For Vertex And Glaxo Wellcomes Second-Generation HIV Protease Inhibitor Agenerase TM
10. The Second Visible Human Project Conference
11. Researchers Take A Second Look At Homocysteines Link To Heart Disease

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/24/2017)... -- Research and Markets has announced the addition of ... - Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle ... around 15.1% over the next decade to reach approximately $1,580 million ... estimates and forecasts for all the given segments on global as ...
(Date:3/22/2017)... , March 21, 2017   Neurotechnology , ... recognition technologies, today announced the release of the ... which provides improved facial recognition using up to ... a single computer. The new version uses deep ... accuracy, and it utilizes a Graphing Processing Unit ...
(Date:3/20/2017)... At this year,s CeBIT Chancellor Dr. Angela ... The Chancellor came to the DERMALOG stand together with the Japanese Prime ... partner country. At the largest German biometrics company the two government leaders ... iris recognition as well as DERMALOG´s multi-biometrics system.   ... ...
Breaking Biology News(10 mins):
(Date:4/28/2017)... ... 2017 , ... Cynvenio Biosystems, Inc. a leader in personalized medicine ... monitoring (NEAT) study in partnership with Allentown, PA-based TME Research . The multi-center ... monitored over two years with Cynvenio’s ClearID Breast Cancer blood test. The study goal ...
(Date:4/27/2017)... ... April 27, 2017 , ... ... digital pathology, today announced their digital pathology technology has the potential to eliminate ... five medical centers in The Netherlands as part of the 2017 ISBI ...
(Date:4/27/2017)... ... April 27, 2017 , ... Sierra Instruments ... on capillary thermal mass flow technology provide exponentially more accurate mass flow data ... 80% of all industrial processes—such as those involving chemical reactions, combustion, respiration, pharmaceutical, ...
(Date:4/27/2017)... 2017  Kinexum, a distinguished resource for research, development ... appointment of Thomas C. Seoh as President ... Kinexum founder, who becomes Executive Chairman and will continue ... Thomas Seoh commented, "I am ... and lead the firm,s remarkable team of life science ...
Breaking Biology Technology:
Cached News: